This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Harris, J T Articles by Rajagopal, M R Search for Related Content PubMed PubMed Citation Articles by Harris, J T Articles by Rajagopal, M R Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Cancer Hazardous Substances DB MORPHINE Social Bookmarking                         What's this?

Intravenous morphine for rapid control of severe cancer pain

Assir Central Hospital, Post Box 34, Abha, Kingdom of Saudi Arabia; Payickaran House, Punnapra, Alleppey 688 004, Kerala, Indiaharrisjt{at}rediffmail.com

K Suresh Kumar

M R Rajagopal

Pain and Palliative Care Clinic, Medical College, Calicut, India

This randomized controlled trial compared intravenous route with oral route for initial dose titration of morphine in 62 patients with end-stage cancer and severe pain. Patients in the intravenous group received 1.5 mg intravenous bolus doses of morphine every ten minutes till pain relief was total or until they became drowsy. After that they got oral morphine at a dose equal to the total initial intravenous requirement four-hourly. Patients in the oral group got oral morphine 5 mg doses (if opioid-naÖve) or 10 mg (if already on weak opioid) four hourly. Patients in both groups had the option to receive rescue doses of their regular oral dose as and when needed, if necessary hourly. Twenty-seven of 31 in the intravenous group had either total or satisfactory pain relief by the end of one hour, whereas only eight of 31 in the oral group had a similar result. After 24 hours and later both groups had similar results. There was no immediate serious side effect in any of the patients. The late side effects were similar in the two groups. In the intravenous group, the ratio of initial intravenous dose requirement to the subsequent regular single oral dose after two days centred around 1:1 (range 1:0.5-1:3.3). This study found the intravenous method to be safe, effective and superior to the traditional method in providing immediate relief to severe cancer pain.

Key Words: analgesia • cancer pain • developing world • morphine • parenteral morphine • WHO analgesic ladder

Palliative Medicine, Vol. 17, No. 3, 248-256 (2003)
DOI: 10.1191/0269216303pm695oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?